In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Electrocardiogram recording by patients boosts atrial fibrillation diagnosis (REHEARSE-AF)

Barcelona, Spain – 29 Aug 2017: Electrocardiogram (ECG) recording by patients with remote analysis by professionals identifies more atrial fibrillation (AF) than routine care, according to late-breaking results from a randomised trial presented today in a Hot Line - LBCT Session at ESC Congress (1) and published in Circulation. The approach has the potential to reduce AF-related strokes by starting preventative treatment earlier.

AF is a common and serious heart arrhythmia that accounts for up to one-third of strokes. It can lead to the formation of blood clots in the heart, which break off and travel to the brain, causing a stroke or transient ischaemic attack. In more than 25% of AF-related strokes, AF is not picked up before the stroke because there are no obvious symptoms.

“Strokes from AF are often larger, more severe, and harder to survive than other strokes,” said chief investigator Prof Julian Halcox, consultant cardiologist and professor of cardiology at Swansea University Medical School, UK. “There is good evidence that identifying AF before symptoms develop and treating patients with oral anticoagulants and other therapies could greatly reduce the risk of stroke and associated disability and death.”

The REHEARSE-AF trial (2) investigated whether twice weekly ECG recording by patients with remote analysis, compared to routine care, increases the diagnosis of AF in patients 65 years of age or older with stroke risk factors.

The trial included 1 003 patients recruited from local primary care practices. Participants were 65 years of age or older, had stroke risk factors, (3) did not have a prior diagnosis of AF, were not receiving anticoagulant treatment, and did not have any contraindications to anticoagulants. Patients were randomised to 12 months of ECG recording (intervention group) or routine visits to local healthcare providers (control group).

Patients in the intervention group were trained to use the AliveCor Kardia Mobile heart monitor (figure 1) to record an ECG twice weekly, as well as if they experienced symptoms such as palpitations. The heart monitor was attached to a WiFi enabled iPod which transmitted the ECGs to trained investigators for analysis. The process of recording and transmitting an AliveCor ECG took around two to three minutes, and provided a 30 second snapshot of the heart rhythm the patient was in at the time of recording. Patients were called in for clinical review if an ECG diagnosis of AF (or other concerning arrhythmia) was made.

The primary endpoint was diagnosis of atrial fibrillation. The cost of an AF diagnosis in the intervention group was also evaluated. Patient experience was evaluated at the end of the study using a Likert scale.

During the 12 months, 19 patients in the intervention group were diagnosed with AF compared to five in the control group (hazard ratio 3.9, 95% confidence interval 1.4–10.4, p = 0.007), despite having a similar number of risk factors (figure 2). Just over 2% of the ECGs recorded and submitted were considered uninterpretable. (4) This was usually due to electrical interference at the time of ECG recording, most often from muscle tremor due to gripping the device too firmly. Health economic modelling showed that each AF diagnosis in the intervention group cost around £8,255.

“Patients in the ECG recording arm were almost four times as likely to have AF diagnosed over the course of the year as those in the control arm,” said Prof Halcox.

Most patients recording their ECGs did not feel restricted or anxious and were generally satisfied, while control patients were slightly more anxious about the risk of heart rhythm abnormalities and stroke and would have preferred to have been enrolled in the regular monitoring group.

Prof Halcox said: “Our study was not designed to evaluate outcomes, but the increase in AF diagnosis with patient ECG monitoring suggests that it has the potential to reduce stroke through earlier diagnosis and treatment with oral anticoagulation. A much larger outcome trial is needed to evaluate the clinical impact and cost-effectiveness of this approach.”


Figure 1: The AliveCor Kardia Mobile heart monitor

Fig 1 - HL4 Rehearse AF.JPG

















Figure 2: Time to diagnosis of AF in ECG monitoring (iECG) and control (RC) groups

Fig 2 HL4 Rehearse AF.JPG















Hazard ratio = 3.9, p = 0.007; Key: AF (atrial fibrillation); iECG (intervention ECG group); RC (routine care group)


Notes to editor

Sources of funding: The study was funded by a joint grant from the Welsh Government Health Technology and Telehealth Fund and AliveCor Inc. (Mountain View, CA, USA). The study was sponsored by Abertawe Bro Morgannwg University Health Board and overseen by a trial steering committee. A representative from AliveCor Inc. sat on the trial steering committee, but the company was not involved in the analysis of trial data or reporting of the results.

Disclosures: The investigators have no financial disclosures to report other than this research grant from AliveCor.

References and notes:
(1) The study “Assessment of REmote HEArt Rhythm Sampling using the AliveCor heart monitor to scrEen for Atrial Fibrillation” will be presented during:
• The press conference Hot Line - Late Breaking Clinical Trials 4 on Monday 28 August from 13:00 to 14:00.
• The session Hot Line - Late Breaking Clinical Trials 4 on Tuesday 29 August from 08:30 to 10:00 in Barcelona – Main Auditorium.
(2) REHEARSE-AF trial: Assessment of REmote HEArt Rhythm Sampling using the AliveCor heart monitor to scrEen for Atrial Fibrillation
(3) Patients were eligible for the study if they scored 2 or more on the clinical risk score CHA2DS2-VASc, which gives points to the following stroke risk factors: congestive heart failure, hypertension, age ≥75 (2 points), diabetes, stroke (2 points), vascular disease, age 65–74, and female sex.
(4) The AliveCor App contains automated ECG analysis software, so patients can reacquire their ECG if the initial recording is considered uninterpretable.

ESC Press Office
For more information, please contact the ESC Press Office:
For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856
The press conference timetable is available here.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2017
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.